Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 4/20 | 0.52 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.52 |
| ▸ | CCR6 | P51684 | 16/20 | 0.51 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5914717 | 0.87 | CXCR2 (0.64) | CXCR2CCR6CXCR1 | |
| SCHEMBL5711797 | 0.85 | CXCR2 (0.60) | CXCR2CX3CR1CCR6CXCR1 | |
| SCHEMBL5711772 | 0.84 | CXCR2 (0.50) | CXCR2CCR6 | |
| SCHEMBL5711800 | 0.83 | CXCR2 (0.66) | CXCR2CX3CR1CCR6CXCR1 | |
| SCHEMBL5711770 | 0.79 | CCR6 (0.56) | CXCR2CX3CR1CCR6CXCR1 | |
| SCHEMBL5711776 | 0.77 | CXCR2 (0.72) | CXCR2CCR6CXCR1 | |
| SCHEMBL5711768 | 0.77 | CXCR2 (0.48) | CXCR2CX3CR1CCR6CXCR1 | |
| SCHEMBL4619687 | 0.77 | CXCR2 (0.58) | CXCR2CX3CR1CCR6CXCR1 | |
| SCHEMBL6138369 | 0.76 | CXCR2 (0.47) | CXCR2CCR6 | |
| SCHEMBL3882238 | 0.75 | CXCR2 (0.76) | CXCR2CCR6CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1351933-B1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060084641-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-04-20 | — | — | US | disclosed |
| EP-1351933-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040048897-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | disclosed |
| EP-1351933-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002057230-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048897-A1 | Il-8 receptor antagonists | CXCL8, CCR8, TLR8 | CXCR2 11/4885CX3CR1 29/4885CCR6 36/4885 |
| US-20060084641-A1 | IL-8 receptor antagonists | CXCL8, CCR8, TLR8 | CXCR2 11/4885CX3CR1 29/4885CCR6 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.